Print Page     Close Window     

SEC Filings

6-K
AC IMMUNE SA filed this Form 6-K on 08/09/2017
Entire Document
 
 

 

Statements of Cash Flows

 

   For the Six Months
Ended June 30,
   2017  2016
in CHF thousands   
Operating activities          
Net income/(loss) for the period    (21,782)   6,774 
Adjustments to reconcile net loss for the period to net cash flows:          
Depreciation of property, plant and equipment    241    139 
Finance result, net    5,619    (89)
Share-based compensation expense    254    150 
Changes in pensions    178    41 
Accrued interest on long-term debt    72    - 
Changes in working capital:          
Prepaid expenses    (686)   (1,764)
Accrued income    (190)   (155)
Other current receivables    (873)   (15,409)
Other current liabilities    (699)   272 
Deferral of unearned revenue (current)    (180)   2,049 
Accounts payable    (3,050)   906 
Long-term financing obligation    189    - 
Cash used in operating activities    (20,907)   (7,086)
Financial costs    (5)   (116)
Net cash flows used in operating activities    (20,912)   (7,202)
           
Investing activities          
Purchases of property, plant and equipment    (1,524)   (307)
Rent deposit    (40)   - 
Net cash flows used in investing activities    (1,564)   (307)
           
Financing activities          
Proceeds from issuance of preferred Series E shares    -    13,344 
Transaction costs of issue of shares    -    (472)
Proceeds from issuance of shares    40    199 
Cost on issue of shares - option plan    -    (18)
Proceeds from issuance of common shares    -    106 
Proceeds from long-term financing    51    - 
Net cash flows provided by financing activities    91    13,159 
           
Net increase/(decrease) in cash and cash equivalents    (22,385)   5,650 
           
Cash and cash equivalents at January 1    152,210    76,522 
Exchange gain/(loss) on cash and cash equivalents    (5,645)   205 
Cash and cash equivalents at June 30    124,180    82,377 
Net decrease/(increase) in cash and cash equivalents    (22,385)   5,650 

 

Additional Information:

 

A non-cash increase to long-term financing obligation totaling CHF 146 thousand was recognized in the Balance Sheet with a corresponding increase to finance receivable. Please see Note 7 for further discussion.

 

The accompanying notes form an integral part of these Interim Condensed Financial Statements (unaudited).  

 

 5


© AC Immune 2015